# SR-45023A in Treating Patients With Locally Advanced or Metastatic Solid Tumors

> **NCT00004049** · PHASE1 · COMPLETED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 36 (estimated)

## Conditions studied

- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** apomine

## Key facts

- **NCT ID:** NCT00004049
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-04
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2018-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00004049

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00004049, "SR-45023A in Treating Patients With Locally Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00004049. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*